Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E67.25 EPS (ttm)1.17 Insider Own0.40% Shs Outstand215.66M Perf Week3.38%
Market Cap16.97B Forward P/E27.42 EPS next Y2.87 Insider Trans-10.67% Shs Float213.33M Perf Month6.82%
Income252.90M PEG1.95 EPS next Q0.49 Inst Own94.80% Short Float2.72% Perf Quarter-6.04%
Sales2.00B P/S8.49 EPS this Y133.20% Inst Trans0.62% Short Ratio4.55 Perf Half Y20.99%
Book/sh9.74 P/B8.08 EPS next Y27.68% ROA9.80% Target Price88.81 Perf Year16.00%
Cash/sh7.33 P/C10.73 EPS next 5Y34.50% ROE13.40% 52W Range57.00 - 88.83 Perf YTD23.73%
Dividend- P/FCF43.30 EPS past 5Y23.80% ROI6.30% 52W High-11.43% Beta1.28
Dividend %- Quick Ratio5.20 Sales past 5Y39.60% Gross Margin96.10% 52W Low38.04% ATR2.58
Employees1367 Current Ratio5.20 Sales Q/Q30.20% Oper. Margin13.50% RSI (14)48.71 Volatility2.45% 3.32%
OptionableYes Debt/Eq0.01 EPS Q/Q342.50% Profit Margin12.70% Rel Volume0.86 Prev Close76.83
ShortableYes LT Debt/Eq0.01 EarningsApr 30 BMO Payout0.00% Avg Volume1.27M Price78.68
Recom2.20 SMA200.53% SMA50-3.16% SMA2007.57% Volume1,093,573 Change2.41%
May-21-19Initiated Credit Suisse Neutral $75
May-03-19Downgrade Barclays Overweight → Equal Weight $90 → $82
Apr-11-19Initiated Stifel Hold $82
Apr-03-19Downgrade RBC Capital Mkts Outperform → Sector Perform $89
Jan-24-19Upgrade William Blair Mkt Perform → Outperform
Jan-24-19Upgrade Gabelli & Co Hold → Buy $105
Jan-16-19Downgrade UBS Buy → Neutral
Jan-03-19Upgrade Guggenheim Neutral → Buy
Oct-22-18Upgrade Raymond James Outperform → Strong Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $73
Sep-25-18Initiated Leerink Partners Mkt Perform
Aug-15-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Aug-01-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-26-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Jun-11-18Upgrade Evercore ISI In-line → Outperform
Apr-09-18Reiterated Credit Suisse Outperform $145 → $78
Apr-09-18Downgrade Gabelli & Co Buy → Hold
Apr-06-18Downgrade William Blair Outperform → Mkt Perform
Apr-06-18Downgrade Guggenheim Buy → Neutral
May-21-19 08:46AM  Merck's Keytruda Fails in Late-Stage Breast Cancer Study Zacks
May-20-19 02:15PM  Why I Like Incyte Corporation (NASDAQ:INCY) Simply Wall St.
07:30AM  Data from Incytes Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology Business Wire
May-18-19 09:50AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
May-16-19 12:00PM  Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA Business Wire
May-14-19 07:08AM  Here are Mondays worst stock-market performers as U.S.-China trade dispute escalates MarketWatch
May-13-19 06:30AM  BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders GlobeNewswire -6.11%
May-09-19 08:00AM  Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors GlobeNewswire
May-08-19 09:48AM  Why Incyte Stock Lost 11% in April Motley Fool
May-06-19 01:36PM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
May-02-19 09:31PM  Edited Transcript of INCY earnings conference call or presentation 30-Apr-19 12:00pm GMT Thomson Reuters StreetEvents
11:18AM  The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex Zacks
08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
May-01-19 11:52AM  Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates Zacks
Apr-30-19 07:00PM  Top Biotech Stocks for February 2019 Investopedia
05:35PM  Incyte Corp (INCY) Q1 2019 Earnings Call Transcript Motley Fool
04:09PM  This Biotech Stock Just Topped Expectations And Became Profitable Investor's Business Daily
03:18PM  5 Biotech Stocks for a Long-Lived Portfolio InvestorPlace
10:10AM  Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y Zacks
07:44AM  Incyte: 1Q Earnings Snapshot Associated Press
07:00AM  Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs Business Wire
03:05AM  Incyte Earnings, Revenue Beat in Q1 Investing.com
Apr-29-19 06:42PM  Incyte Expected to Earn 29 Cents a Share TheStreet.com
06:14PM  Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings? Zacks
04:14PM  Why Novartis Earnings Provided A Bullish Signal For This Biotech Stock Investor's Business Daily
08:25AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
Apr-26-19 04:07PM  Will HIV Franchise Sales Drive Gilead's (GILD) Q1 Earnings? Zacks
02:01PM  Is a Beat in Store for Glaxo (GSK) This Earnings Season? Zacks
Apr-25-19 09:42AM  Exelixis (EXEL) to Report Q1 Earnings: What's in Store? Zacks
09:27AM  The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences Zacks
09:26AM  The Zacks Analyst Blog Highlights: CommScope, Incyte, Cigna, Columbia Sportswear and Synopsys Zacks
Apr-24-19 04:32PM  What's in Store for Vertex (VRTX) This Earnings Season? Zacks
12:06PM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
11:43AM  Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock? Zacks
09:15AM  Solid Earnings Boost S&P, NASDAQ to New Closing Highs Zacks
09:11AM  5 Biotech Stocks Defying the Medicare-for-All Scare Zacks
09:04AM  Can S&P 500 and Nasdaq Sustain Record Run? 5 Top Picks Zacks
Apr-23-19 10:59AM  Amgen (AMGN) to Report Q1 Earnings: What's in the Cards? Zacks
10:44AM  What's in the Cards for AstraZeneca (AZN) in Q1 Earnings? Zacks
10:32AM  Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
09:27AM  The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap Zacks
Apr-22-19 11:08AM  Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store? Zacks
10:33AM  Is a Beat in Store for AbbVie (ABBV) This Earnings Season? Zacks
10:17AM  Biogen (BIIB) to Report Q1 Earnings: What's in the Cards? Zacks
09:11AM  5 Must-Buy Stocks Amid Exaggerated Economic Slowdown Zacks
Apr-19-19 11:53AM  Should Incyte (NASDAQ:INCY) Be Disappointed With Their 56% Profit? Simply Wall St.
09:27AM  Health-care drama has now spread to biopharma stocks MarketWatch
Apr-12-19 11:08AM  Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group Zacks
Apr-11-19 09:46AM  Concert Pharma Initiates Early-Stage Schizophrenia Study Zacks
08:00AM  Incyte to Report First Quarter Financial Results Business Wire
Apr-08-19 03:09PM  Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling MarketWatch
Apr-03-19 02:21PM  Puts Active After RBC Downgrades Incyte Stock Schaeffer's Investment Research
Apr-02-19 02:58PM  BriaCell Announces Clinical Trial Collaboration Agreement with Incyte GlobeNewswire
Apr-01-19 01:30PM  Did Hedge Funds Drop The Ball On Incyte Corporation (INCY) ? Insider Monkey
07:00AM  Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019 GlobeNewswire
Mar-16-19 09:30AM  Why Is Incyte (INCY) Up 1.7% Since Last Earnings Report? Zacks
Mar-14-19 10:55AM  Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:45AM  Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica Zacks
Mar-13-19 10:55AM  10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run Zacks
09:45AM  4 Toxic Stocks to Abandon or Sell Short for Solid Gains Zacks
Mar-08-19 01:40PM  Why Incyte Corporation (NASDAQ:INCY) Is A Financially Healthy Company Simply Wall St.
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos
06:42AM  Pullback Strategies: 10 Stocks That Could Fall the Fastest Investopedia
Mar-05-19 08:42AM  Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda Zacks
05:00AM  Incyte- Insights into Small Molecule Drugs MoneyShow
Mar-01-19 07:00AM  New Research Coverage Highlights Nasdaq, Constellation Brands, Incyte, IMAX, HNI, and Frank's International N.V Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-28-19 10:30AM  Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019 Business Wire
08:00AM  Data from Incytes Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019 Business Wire
Feb-27-19 09:27AM  Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica Zacks
07:25AM  3 Big Stock Charts for Wednesday: Cabot Oil & Gas, Incyte and Sempra Energy InvestorPlace
12:06AM  Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-26-19 09:26AM  4 Toxic Stocks to Discard or Sell Short for Solid Gains Zacks
Feb-21-19 09:12AM  Merck Gets Priority Review for Keytruda in Third-Line SCLC Zacks
Feb-20-19 12:45PM  6 Companies With 20% Or More Earnings Growth Investopedia
08:39AM  Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study Zacks
Feb-19-19 09:02AM  Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why Zacks
08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
Feb-18-19 08:10AM  Merck Gets Priority Review for Keytruda Combo in Kidney Cancer Zacks
07:00AM  Incyte's Undervalued as Pipeline Progresses Morningstar
05:10AM  Edited Transcript of INCY earnings conference call or presentation 14-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
Feb-14-19 09:25PM  Incyte (INCY) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:11PM  Highly Rated Biotech Turns Profitable But Earnings Lag Estimates Investor's Business Daily
01:49PM  Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat Zacks
10:38AM  Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored Bloomberg
08:20AM  Incyte (INCY) Q4 Earnings Lag Estimates Zacks
07:26AM  Incyte: 4Q Earnings Snapshot Associated Press
07:00AM  Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs Business Wire
02:02AM  Incyte Earnings, Revenue beat in Q4 Investing.com
Feb-13-19 05:22PM  Incyte Expected to Earn 17 Cents a Share TheStreet.com
03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
Feb-12-19 09:24AM  Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica Zacks
09:12AM  Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer Zacks
Feb-11-19 03:58PM  Is a Disappointment in Store for Incyte (INCY) Q4 Earnings? Zacks
08:58AM  4 Toxic Stocks to Abandon or Sell Short for Solid Gains Zacks
08:45AM  Why Incyte Stock Gained 27% in January Motley Fool
Feb-08-19 04:33PM  Incyte Down as FDA Extends Review Period of Jakafi for GVHD Zacks
Feb-07-19 04:23PM  FDA Delays This Biotech's Drug Why Analysts Are Still Bullish Investor's Business Daily
11:18AM  FDA resets decision date on Incyte's GVHD treatment application American City Business Journals
07:00AM  Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease Business Wire
Feb-06-19 06:16PM  MacroGenics stock spikes from positive results of cancer drug trial American City Business Journals
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SWAIN PAULA JEVP, Human ResourcesApr 01Option Exercise18.3210,000183,20044,731Apr 02 04:51 PM
SWAIN PAULA JEVP, Human ResourcesApr 01Sale87.0110,000870,10036,513Apr 02 04:51 PM
SWAIN PAULA JEVP, Human ResourcesMar 01Option Exercise18.3210,000183,20046,513Mar 05 04:45 PM
SWAIN PAULA JEVP, Human ResourcesMar 01Sale86.6810,000866,80036,513Mar 05 04:45 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Option Exercise2.8040,000112,00029,288,793Feb 27 05:19 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Option Exercise18.3210,000183,20041,124Feb 05 04:36 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Sale81.1910,000811,90031,124Feb 05 04:36 PM
Flannelly Barry PEVP & General Manager USJan 28Sale80.001,00080,0008,944Jan 30 04:22 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Option Exercise17.7915,354273,14849,763Jan 22 06:04 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Sale77.6115,3541,191,62434,409Jan 22 06:04 PM
Trower PaulPrincipal Accounting OfficerJan 15Option Exercise17.795,813103,41319,713Jan 17 04:15 PM
Trower PaulPrincipal Accounting OfficerJan 15Sale75.005,813435,97513,900Jan 17 04:15 PM
Flannelly Barry PEVP & General Manager USJan 08Sale75.561,714129,5109,944Jan 10 04:11 PM
Trower PaulPrincipal Accounting OfficerJan 07Option Exercise17.799,187163,43723,359Jan 08 04:42 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Option Exercise17.7910,000177,90045,217Jan 08 04:46 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Sale75.0010,000750,00035,217Jan 08 04:46 PM
Trower PaulPrincipal Accounting OfficerJan 07Sale75.009,187689,02514,172Jan 08 04:42 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Option Exercise18.3230,000549,60062,324Jan 08 04:37 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Sale70.0030,0002,100,00032,324Jan 08 04:37 PM
BIENAIME JEAN JACQUESDirectorNov 08Buy68.771,00068,7656,668Nov 09 04:21 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Option Exercise18.3210,000183,20042,324Oct 05 04:29 PM
Trower PaulPrincipal Accounting OfficerOct 03Option Exercise17.7910,000177,90024,172Oct 05 04:30 PM
Trower PaulPrincipal Accounting OfficerOct 03Sale70.0010,000700,00014,172Oct 05 04:30 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Sale70.0010,000700,00032,324Oct 05 04:29 PM
Flannelly Barry PEVP & General Manager USOct 03Sale70.001,00070,00012,427Oct 05 04:23 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Option Exercise18.3210,000183,20042,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Sale73.2110,000732,10032,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Option Exercise18.3210,000183,20042,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Sale70.0010,000700,00032,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Option Exercise18.3210,000183,20042,963Jul 11 04:41 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Sale71.1110,000711,10032,963Jul 11 04:41 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 09Sale71.3460643,2328,103Jul 11 04:39 PM
BROOKE PAUL ADirectorJun 04Option Exercise2.8020,00056,000217,859Jun 06 04:33 PM